Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06586216 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

A Phase 1 study of COVID-19, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
3
Study locations

NCT06586216 is a Phase 1 study of COVID-19 that has completed, run by Pfizer. The registered enrollment target is 16 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06586216, a Phase 1 study of COVID-19, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
3
Study locations

Study Summary

The purpose of the study is to learn about: * how PF-07817883 is processed in the body of adult participants. * the safety of PF-07817883. These participants will have different levels of kidney function loss: * moderate * severe * none or healthy Participants with moderate, severe or no loss of kidney function may be taken into one of 3 groups. This study is seeking for participants who: * are male or female of 18 to 90 years of age. * have different levels of damage to kidney function or for one of the groups, no damage * are willing to follow the requirements of the study including stay at clinic for 5 nights and 6 days. About, 8 participants may be selected in groups 2 and 3. In group 1, around 8 to 12 participants may be selected. If participants agree to take part in the study, it may take up to 4 weeks to complete all the tests to confirm if they are fit to be in the study. If they seem to be fit for the study, participants will be admitted to a clinic research unit (CRU) at least 8 hours before dosing. On Day 1, participants will receive a single amount of study medicine (Day 1). A series of blood samples will be collected before and after giving medicines. Participants will be discharged from the CRU on Day 5. A follow-up phone call (or CRU visit, if needed), will occur 28-35 days after taking the medicine. The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks.

Conditions Studied

COVID-19

Interventions

  • DRUG PF-07817883

Study Locations (3)

Florida

  • Clinical Pharmacology of Miami - Miami
  • Genesis Clinical Research, LLC - Tampa

Minnesota

  • Prism Research LLC dba Nucleus Network - Saint Paul

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2024-09-10
Est. Completion 2025-02-13
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06586216

The ClinicalTrials.gov registry entry for NCT06586216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which PF-07817883 is the first listed.

NCT06586216 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06586216 about?

NCT06586216 is a clinical study titled "A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.". The purpose of the study is to learn about: * how PF-07817883 is processed in the body of adult participants. * the safety of PF-07817883. These participants will have different levels of kidney function loss: * moderate * severe * none or healthy Participants with moderate, severe or no loss of ...

What is the current status of trial NCT06586216?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-09-10. Estimated completion is 2025-02-13.

What conditions does trial NCT06586216 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT06586216?

The interventions under investigation include: PF-07817883 (DRUG).

Who is sponsoring clinical trial NCT06586216?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06586216 being conducted?

This trial has 3 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.